CAMP

Camp4 Therapeutics Corp

NasdaqAdd to watchlist

Technology · Communication Equipment

$4.24

+$0.21+5.21%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

4 open-market sales on file ($2.5M), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$4.24

−$0.08−1.85%over 1M

Session

Day range91% of range

$3.95$4.27

Fundamentals

Visualize fundamentals and more

Market cap: 245.62M
P/E ratio: -

Revenue grew +436.50% in FY2025, +427.23% faster than its sector. The median across Technology companies this platform tracks is +9.27%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 38
dropped: 45
re-drafted: 54

Out of 288 passages in this year’s Item 1A.

New this year

• contract with third-party manufacturers for preclinical and clinical supply to support any future product candidates we may develop and for commercial supply with respect to any such product candidates that receive regulatory approval;

82 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Data privacy
Export controls
Labour
Going concern
China

And 5 more.

FDA approval
We are still in the early stages of development of our product candidates and our lead product candidate, CMP-002, has not yet entered clinical trials. We have no products licensed for commercial sale and have not generated any revenue to date, and we …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Aug 31 Gold Kelly bought 10,000 shares Insider trading Form 4 Chief Financial Officer, about $40k
Aug 13 Results announcement Company filing 8-K
Aug 13 Quarterly report Company filing 10-Q

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Camp4 Therapeutics Corp investor relations

What CAMP has filed with the SEC. This is not Camp4 Therapeutics Corp’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Camp4 Therapeutics Corp

Also filed under Communication Equipment, ranked by how closely they sit beside CAMP.

LITELumentum Holdings Inc.compare with CAMP
CSCOCisco SYSTEMS, Inc.compare with CAMP
NOK

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Data privacy
Export controls
Labour
Going concern
China

And 5 more.

FDA approval
We are still in the early stages of development of our product candidates and our lead product candidate, CMP-002, has not yet entered clinical trials. We have no products licensed for commercial sale and have not generated any revenue to date, and we …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

CRDOCredo Technology Group Holding Ltdcompare with CAMP

HPEHewlett Packard Enterprise Cocompare with CAMP

Ask about Camp4 Therapeutics Corp

The assistant answers from what CAMP has actually filed: 3 annual reports filed with the SEC, 11 Form 4 filings from the last year and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from CAMP's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Camp4 Therapeutics Corp each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Camp4 Therapeutics Corp

Be told the moment a CAMP insider trades
Put Camp4 Therapeutics Corp on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Camp4 Therapeutics Corp's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Camp4 Therapeutics Corp's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Aug 31 Gold Kelly bought 10,000 shares Insider trading Form 4 Chief Financial Officer, about $40k
Aug 13 Results announcement Company filing 8-K
Aug 13 Quarterly report Company filing 10-Q

21 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 38
dropped: 45
re-drafted: 54

Out of 288 passages in this year’s Item 1A.

New this year

• contract with third-party manufacturers for preclinical and clinical supply to support any future product candidates we may develop and for commercial supply with respect to any such product candidates that receive regulatory approval;

82 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add